Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers – Reports executive leadership changes and/or compensation-related matters at Baxter International Inc. Item 8.01: Regulation FD Disclosure – Contains material information being disclosed to investors in accordance with Regulation Fair…

Our analysis rates this filing CAUTIOUS. Baxter's elevated concern level (6.8/10) reflects a material executive transition with multiple compounding risks that warrant investor scrutiny, though the situation does not approach critical/existential threat levels. The primary concern is the confluence…

Concern level: HIGH (6.8/10). Key factors: One high-severity risk identified (CFO Transition and Leadership Continuity Risk, severity 7/10) with material governance implications; Overall risk trend INCREASING with risk score of 6.8/10; Compressed 2-week transition period between interim CFO departure (Sept 15) and new CFO start (Oct 1) creates operational vulnerability.

Notable risk changes: Material executive transition: Interim CFO Anita Zielinski departing September 15, 2026, with only 2-week gap before new external CFO John Rogers starts October 1, 2026. CEO Andrew Hider assumes interim CFO role during gap, creating dual-role concentration risk.; New CFO is external hire with limited healthcare/medical device industry experience and no Baxter background. Most recent CFO tenure…